Hørmann Thomsen Trine, Kjær Troels Wesenberg, Bastrup Jørgensen Lene, Haahr Anita, Winge Kristian
Department of Clinical Neurophysiology and Neurology, Zealand University Hospital, Roskilde, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Parkinsons Dis. 2020 Jul 27;2020:7140984. doi: 10.1155/2020/7140984. eCollection 2020.
Individuals with Parkinson's Disease (PD) have bradykinesia during mobility tasks in the morning before intake of dopaminergic treatment and have difficulties managing Activities of Daily Living (ADLs). Early morning off (EMO) refers to off-states in the morning where the severity of bradykinesia is increased and causes a decrease in mobility related to wearing off of effects of medication. Measurements from devices capable of continuously recording motor symptoms may provide insight into the patient's response to medication and possible impact on ADLs.
To test whether poor or slow response to medication in the morning predicts the overall ADL-level and to assess the association between change in bradykinesia score (BKS) and the risk of having disabilities within three selected ADL-items.
In this cross-sectional study, the sample consists of 34 patients with light to moderate PD. Data collection encompasses measurements from the Parkinson KinetiGraph, and the ADL-limitations are assessed by the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part II.
The association between UPDRS- II and BKS from the algorithm was -0.082 ( < 0.01), 95% CL:-0.113; -0.042). The individuals experienced disabilities in performing "Speech" (=0.004) and "Doing hobbies" (=0.038) when being slow or poor responders to dopaminergic therapy. The PD patients' L-dopa equivalent dose seems to be a strong predictor of the ADL-level in the morning.
Slow response to the medication dosages in the morning is correlated with disabilities in the overall ADL-level in PD. The combination of PD-drugs and precise, timely dosages must be considered in the improvement of the ADL-level in PD patients.
帕金森病(PD)患者在早晨服用多巴胺能治疗药物前进行移动任务时存在运动迟缓,且在日常生活活动(ADL)管理方面存在困难。清晨“关期”(EMO)是指早晨出现的“关”状态,此时运动迟缓的严重程度增加,导致与药物疗效减退相关的活动能力下降。能够连续记录运动症状的设备所提供的测量结果,可能有助于深入了解患者对药物的反应以及对ADL的潜在影响。
测试早晨对药物的反应不佳或迟缓是否可预测整体ADL水平,并评估运动迟缓评分(BKS)变化与三项选定ADL项目中出现残疾风险之间的关联。
在这项横断面研究中,样本包括34例轻至中度PD患者。数据收集包括帕金森运动记录仪的测量结果,ADL受限情况通过运动障碍协会统一帕金森病评定量表(MDS-UPDRS)第二部分进行评估。
算法得出的UPDRS-II与BKS之间的关联为-0.082(<0.01),95%置信区间为:-0.113;-0.042)。多巴胺能治疗反应缓慢或不佳的个体在进行“言语”(=0.004)和“从事爱好活动”(=0.038)时存在残疾。PD患者的左旋多巴等效剂量似乎是早晨ADL水平的有力预测指标。
早晨对药物剂量反应缓慢与PD患者整体ADL水平的残疾情况相关。在改善PD患者的ADL水平时,必须考虑PD药物与精确、适时剂量的结合。